NYSE:NVO 10 February 2026

Veru Shares Pop on Novo Wegovy Tie-Up, Uncertainty Lingers Over Key Clause

Veru shares soared 88% to $4.23 after a Novo Nordisk deal to supply Wegovy free for Veru’s Phase 2b obesity study, with analysts calling it “external validation” and maintaining $24–$25 price targets, but risks remain as Veru keeps full rights to enobosarm and Novo can end the agreement with 60 days’ notice.

5 June 2026

NASDAQ:VERU·NYSE:NVO·Pharmaceuticals·Stock Market

Veru shares jump after Novo Nordisk deal draws traders

Veru shares soared 112% to $4.78 after announcing Novo Nordisk will supply Wegovy at no charge for Veru’s Phase 2b obesity trial, with Veru retaining global rights to enobosarm but granting Novo a right of first negotiation; analysts called the deal a “significant event” and kept $24–$25 targets, while Veru warned trial risks and reimbursement challenges remain.

4 June 2026

NASDAQ:VERU·NYSE:NVO·Stock Market

Novo Nordisk Shares Rise As Ozempic Study Shows 15% Weight Loss In Older Adults

A pooled analysis found semaglutide 2.4 mg led to 15.4% weight loss in adults 65 and older after 68 weeks, compared to 5.1% for placebo. Novo Nordisk B shares rose 3.75% to 301.20 crowns in Copenhagen. The analysis included 358 participants from multiple STEP trials. Novo is seeking to defend its obesity drug franchise as competition with Eli Lilly intensifies.

11 May 2026

NYSE:NVO·Pharmaceuticals

Hims & Hers Health Earnings Today: Why One GLP-1 Question Could Move HIMS Stock

Hims & Hers Health reports first-quarter results Monday after the market close, with Wall Street expecting about $617 million in revenue and EPS of 3 to 4 cents. Investors are watching whether its weight-loss business can grow after it stopped broadly marketing compounded GLP-1 drugs and shifted to FDA-approved options from Novo Nordisk. Hims shares closed at $28.46 Friday, rising to $29.07 after hours.

11 May 2026

Earnings·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Jumps After Wegovy Pill Sales Surprise in Lilly Obesity Fight

Novo Nordisk raised its 2026 outlook after early U.S. sales of its new Wegovy weight-loss pill surpassed 2 million prescriptions since January, beating expectations. Shares jumped as much as 9.2% in Copenhagen. Adjusted first-quarter sales fell 10% to 70.06 billion crowns, but reported net sales rose 24% to 96.82 billion crowns after a U.S. drug pricing provision reversal.

6 May 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.

24 April 2026

Health News·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Novo Nordisk Stock Gets Wegovy Pill Boost as Eli Lilly’s Foundayo Starts Slow

Novo Nordisk’s Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly’s Foundayo at 3,707, according to IQVIA data cited by analysts. Novo’s shares rose $2.24 to $40.76, while Lilly’s fell $35.26 to $882.39. Novo said its oral semaglutide lowered HbA1c by 0.83 points more than placebo in a trial of adolescents with type 2 diabetes. The company plans to seek regulatory approval for pediatric use in 2026.

24 April 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims Adds Lilly’s Zepbound and Foundayo as GLP-1 Price Fight Moves Online

Hims & Hers Health said Thursday its providers can now send prescriptions for Eli Lilly’s Zepbound and Foundayo to LillyDirect, expanding branded obesity drug options on its platform. The move follows a similar deal with Novo Nordisk in March. Hims listed Foundayo from $149 a month and Zepbound from $299. The company previously stopped advertising compounded GLP-1s amid tighter U.S. regulations.

23 April 2026

NYSE:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Hims & Hers Stock Slides as Amazon Enters the GLP-1 Weight-Loss Race

Hims & Hers Health shares fell 1.6% to $30.52 Tuesday after Amazon launched a GLP-1 weight-management program through One Medical, intensifying competition in telehealth weight loss. Amazon said its program will offer same-day pharmacy delivery in nearly 3,000 cities and 24/7 prescription renewals. Eli Lilly and Novo Nordisk shares also declined. Hims is shifting away from compounded GLP-1s toward branded, FDA-approved drugs.

21 April 2026

NASDAQ:AMZN·NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers Health Stock Price Jumps Again as Novo Nordisk Truce Sparks Wall Street Upgrades

Hims & Hers Health shares climbed 5.1% to $27.19 in premarket trading Thursday, after closing up 10.3% Wednesday. The rally follows a deal with Novo Nordisk that ends a patent dispute and will return FDA-approved Wegovy and Ozempic to Hims’ platform later this month. Analysts raised targets but warned branded drugs may bring lower margins. Hims also disclosed an SEC probe and a Justice Department referral.

12 March 2026

NASDAQ:HIMS·NYSE:LLY·NYSE:NVO·Stock Market

Hims & Hers Stock Price Surges Nearly 50% in Two Days After Novo Deal, Analyst Upgrades

Hims & Hers Health shares jumped 5.9% to $23.47 Tuesday after announcing a distribution deal with Novo Nordisk, extending a two-day gain to 49%. Novo withdrew its lawsuit against Hims as part of the pact, which will bring Ozempic and Wegovy to Hims’ platform and phase out most compounded GLP-1 drugs. Analysts raised price targets but warned branded drugs could lower margins. Regulatory risks remain.

11 March 2026

NASDAQ:HIMS·NYSE:NVO·Stock Market

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.

10 March 2026

Health News·NYSE:ABBV·NYSE:LLY·NYSE:NVO·Pharmaceuticals

Eli Lilly stock drops 2% as traders eye China approval and a late-day CFO readout

Eli Lilly shares fell 2.3% to $1,028.07 Monday as health stocks lagged, despite the S&P 500 edging higher. Innovent Biologics won Chinese approval for Jaypirca, a Lilly-partnered cancer drug, after late-stage trial results. Investors remain focused on Lilly’s obesity drug pipeline and upcoming FDA decisions, with orforglipron inventory reaching $1.5 billion ahead of a possible U.S. launch.

2 March 2026

HKG:1801·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Hims & Hers Health shares rose 0.3% premarket after a 2.3% gain Wednesday, closing at $15.82. The company disclosed in its annual report that it faces an SEC investigation, a Justice Department referral, and a patent lawsuit from Novo Nordisk over compounded semaglutide products. BTIG downgraded the stock, citing regulatory risks and weak guidance. Citi cut its price target to $13.25 and maintained a “sell” rating.

26 February 2026

NASDAQ:HIMS·NYSE:NVO·Pharmaceutical Industry·Stock Market

Eli Lilly stock price slips as Zepbound KwikPen FDA nod and Novo trial data keep LLY in focus

Eli Lilly shares fell 1.28% to $1,028.83 Wednesday after the FDA cleared a four-dose Zepbound KwikPen for obesity treatment. Novo Nordisk’s CagriSema showed less weight loss than Lilly’s tirzepatide in a head-to-head trial. Analysts called the gap significant for investors. Lilly said the new KwikPen will cost $299 per month at the 2.5 mg dose.

26 February 2026

NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Novo Nordisk stock slips again as CagriSema miss drives forecast cuts and puts next catalysts in focus

Novo Nordisk shares fell 2.5% to 245.1 Danish crowns Tuesday after its CagriSema obesity drug failed to match Eli Lilly’s tirzepatide in a Phase 3 trial. Barclays cut its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo also reported mid-stage China trial results for its “triple G” obesity drug UBT251, showing up to 19.7% weight loss after 24 weeks.

24 February 2026

NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Eli Lilly shares climbed nearly 5% late Monday after Novo Nordisk reported its obesity drug CagriSema underperformed Lilly’s Zepbound in a head-to-head trial. Novo’s U.S.-listed shares dropped over 16%. CagriSema showed 23% weight loss after 84 weeks, compared to 25.5% for Zepbound. The trial failed to prove CagriSema was not worse than tirzepatide on weight loss.

23 February 2026

Biotechnology·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock steadies premarket after Novo Nordisk patent suit jolts weight-loss push

Hims & Hers Health rose 0.1% to $17.25 premarket after plunging 10.8% Tuesday and 16% Monday. Novo Nordisk sued Hims in a U.S. patent case over compounded versions of Wegovy, intensifying legal and regulatory scrutiny. Traders await court actions, FDA signals, and Hims’ Feb. 23 earnings for updates on weight-loss drug exposure.

11 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.

10 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.